News & Videos - CENTESSA PHARMACEUTICALS PLC ADS - English - Page 3

BOSTON and LONDON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today announced Karen Anderson as its new Chief People Officer. In this newly created position, Karen will lead the Company’s human resources function and help define Centessa’s people and culture strategy. Karen joins Centessa with over 25 years of experience in human...

– Company highlights three significant near-term milestones – – Pivotal program for SerpinPC in hemophilia B advancing; PRESent-5 o bservation study on track to begin this quarter – – Data readout of SerpinPC Phase 2a OLE Study with additional 18-months of continued subcutaneous treatment at American Society of Hematology (ASH) Annual Meeting in December 2022 – – IND submission for LB101, a conditionally tetravalent PD-L1xCD47 bispecific monoclonal antibody, on track for late 2022...

BOSTON and LONDON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), today announced that new data from an additional 18-months of continued treatment with SerpinPC from the open-label extension (OLE) of AP-0101, a Phase 2a study of SerpinPC for the treatment of hemophilia, has been accepted for oral presentation at the 64th American Society of Hematology (ASH) Annual Meeting, to be held in New Orleans, LA, from December 10 - 13, 2022. The ASH presentation will...

BOSTON and LONDON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that members of its management team will participate in the following investor conferences: Event: Jefferies London Healthcare Conference Date: Thursday, November 17, 2022 Location: London, UK Fireside Chat: 10:55 AM GMT Event: Evercore ISI HealthCONx Conference...

– Data demonstrate potent efficacy of small-molecule OX2R agonists in a non-clinical model of narcolepsy type 1 (NT1) – – Company recognizes World Narcolepsy Day on September 22 nd – BOSTON and LONDON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), today announced that non-clinical data from its oral orexin receptor 2 (OX2R) agonist discovery pipeline have been accepted for poster presentation at the 26th Conference of the European Sleep Research Society...

- Registrational studies planned to start in 4Q 2022 - - Two-year data from Phase 2a Open Label Extension study expected in 4Q 2022 - BOSTON and LONDON, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (“R&D”) innovation engine that aims to discover, develop, and ultimately deliver impactful medicines to patients, today announced that the U.S. Food and Drug Administration (FDA) has granted...

BOSTON and LONDON, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (“R&D”) innovation engine that aims to discover, develop, and ultimately deliver impactful medicines to patients, today announced non-clinical pharmacokinetic (PK) and safety data in non-human primates (NHPs) for LB101 (PD-L1xCD47), its first LockBody® candidate for solid tumors. Findings from these data reinforce the...

BOSTON & LONDON, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (“R&D”) innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients, today announced that members of its management team will participate in the following investor conferences: Event: Morgan Stanley 20th Annual Global Healthcare Conference Date: Monday, September 12, 2022 Location: New...

LOS ANGELES, CA / ACCESSWIRE / August 16, 2022 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Centessa Pharmaceuticals plc ("Centessa" or "the Company") (NASDAQ:CNTA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Centessa issued a press release on August 10,...

LOS ANGELES, CA / ACCESSWIRE / August 15, 2022 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Centessa Pharmaceuticals plc ("Centessa" or "the Company") (NASDAQ:CNTA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Centessa issued a press release on August 10,...

LOS ANGELES, CA / ACCESSWIRE / August 12, 2022 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Centessa Pharmaceuticals plc ("Centessa" or "the Company") (NASDAQ: CNTA ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Centessa issued a press release on August 10,...

- Registrational studies of SerpinPC for treatment of Hemophilia B planned for 2H of 2022 – - Oncology pipeline advancing with novel LockBody® technology – - Announces discontinuation of ZF874 for AATD – - Multiple clinical PoC readouts expected across pipeline over next two years – – Cash and cash equivalents of $484.2 million as of June 30, 2022; Cash runway into 2026 – BOSTON and LONDON, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a...

BOSTON and LONDON, July 25, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (R&D) innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients, today announced the appointment of Harris L. Rotman, PhD, as Senior Vice President, Regulatory Affairs. “We are very pleased to welcome Harris to our leadership team as we prepare for our SerpinPC program in Hemophilia...

BOSTON and LONDON, July 01, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (“R&D”) innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients, today announced the appointment of Mathias Hukkelhoven, Ph.D., formerly Senior Vice President, Global Regulatory, Safety & Biometrics at Bristol Myers Squibb (BMS), to its Board of Directors. In addition, the...

BOSTON and LONDON, June 06, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (“R&D”) innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients, today announced that Saurabh Saha, MD, PhD, Chief Executive Officer and Gregory Weinhoff, MD, Chief Financial Officer, will participate in the following investor conferences: Event : Jefferies Healthcare Conference...

BOSTON and LONDON, June 05, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company with a Research & Development (“R&D”) innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients, today announced presentation of the first preclinical data for LB101, PD-L1xCD47 LockBody, in a poster presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting which is taking place...

- Decision based on reassessment of commercial potential of lixivaptan following recent observation of ALT/AST elevations in ALERT Study - - Discontinuation of lixivaptan development expected to significantly reduce cash burn and extend cash runway into 2026 - - Company continues to focus on the development of its innovative high impact rare disease and immuno-oncology pipeline of investigational medicines for patients - BOSTON and LONDON, June 02, 2022 (GLOBE NEWSWIRE) -- Centessa...

– Company advances innovative rare disease and immuno-oncology portfolio toward ‘4x24’ goal of four registrational programs in 2024 – – Poster presentation at ASCO 2022 to highlight LB101 preclinical data in solid tumors; IND planned for late 2022 – – ZF874 for AATD Phase 1 update on track for 2H 2022; interim data from multiple dose cohorts with PiMZ and PiZZ subjects – – Cash and cash equivalents of $544.5 million as of March 31, 2022; Operational cash runway to mid-2024 –...

– Company strengthens strategic focus on rare disease and immuno-oncology assets and details expected upcoming clinical milestones – – SerpinPC registration studies planned to begin in 2H 2022 following recent FDA meeting; initial focus on Hemophilia B with and without inhibitors – – LB101 preclinical data expected to be shared at ASCO 2022; IND planned for late 2022 – – ZF874 Phase 1 update from multiple dose cohorts with PiMZ and PiZZ subjects expected in 2H 2022 – – Pipeline...

BOSTON and LONDON, March 23, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced today that Saurabh Saha, MD, PhD, Chief Executive Officer, will present at the Guggenheim Genomic Medicines & Rare Disease Day on Thursday, March 31, 2022, at 11:00 am Eastern Time. Access to the live webcast of this event, as well as archived recordings, will be available under the “Events” tab on the investor relations section of the Centessa Pharmaceuticals website at...